Company Active LTD

Company profile

Mica Biosystems Limited

Regenerative Medicine | MICA Biosystems

Home of remote-controlled cell therapy developed by world-leading scientists. MICA Biosystems also offers research instrumentation for cell mechanostimulation, and a drug screening platform, acting as an add-on to Caco-2 assays.

CRN
07237355
Founded
2010
Age
16

Overview

Legal name
MICA BIOSYSTEMS LIMITED
Region
Unknown
Registered address
23 ARLEY ROAD
SOLIHULL
WEST MIDLANDS
B91 1NJ
Insolvency history
No

Latest accounts

Financial period: 1 May 2024 to 30 Apr 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
1

Company events

Reference milestones and recent Companies House filing stream events.

6 events
12 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

28 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

01 Oct
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNzk4MDE3NGFkaXF6a2N4

Published 01 Oct 2024 02:59

28 Apr
2010

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2014
Funded years
2014, 2017, 2022, 2025
Age at first award
4 years

Projects

2025 Collaborative R&D Lead participant

Enhancing Drug Discovery: Revolutionising Permeability Predictions with Dynascreen

1 Jan 2025 to 31 Mar 2025

Awarded
£36,198
Total cost £36,198

MICA Biosystems is leading an exciting project to improve the traditional static Caco-2 assay, a key method for testing how drugs are absorbed in the body. We are introducing magnetic nanoparticles to make this test more dynamic, simulating the natural movements in the human gut. This innovation is important for the pharmaceutical industry because it brid...

2022 Collaborative R&D Lead participant

A novel therapy for treatment of degenerative spinal conditions

1 Mar 2022 to 29 Feb 2024

Awarded
£109,065
Total cost £155,807

Low back (LBP) pain and Chronic Low Back Pain (CLBP) represent a common condition linked to musculoskeletal diseases, which affect aged population and represent a major social and economic problem in developed countries. LBP is more common among people aged 40--80 years. The overall number of individuals affected is expected to increase as the population ...

2017 Feasibility Studies Lead participant

Commercial translation of a dynamic ADME screening platform,.DYNASCREEN.

1 Jun 2017 to 30 Nov 2017

Awarded
£26,338
Total cost £58,529

The Caco-2 cell line used by the pharmaceutical industry and support companies is the gold standard for the prediction of drug absorption and permeability in vitro by mimicking the small intestine. However, this model lacks the dynamic motion which represents one of the physiological functions of the small intestine (peristalsis). Our new product developm...

2014 Feasibility Studies Lead participant

Development and validation of a dynamic drug screening platform for ADME testing .

1 Oct 2014 to 30 Jun 2016

Awarded
£72,490
Total cost £123,451

The Caco-2 cell line is the gold standard for the prediction of drug absorption and permeability in vitro by mimicking the small intestine. However, this model lacks the dynamic motion which represents one of the physiological functions of the small intestine (peristalsis). In our research, we investigate the possibility the similarity between the static ...

Product types

Collaborative R&D Feasibility Studies